PUBLIC COMPANY
save$WVEWave Life Sciences Ltd.
$WVE3.7800-2.58%Singapore, SGupdated 3h ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
- phase1A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
- phase2Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy
- phase1A Phase 1 Study of WVE-007 in Adults Living With Overweight or Obesity
- phase2Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
- phase2Study of WVE-003 in Patients With Huntington's Disease
- phase2Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)
- phase2Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
🐶 Hiring Signal
News
- Lilly, Foghorn part ways; Wave’s FDA-approved plansThe pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.biopharma_dive · 2d ago
- GSK continues to stock up on Wave's RNA drugs with liver-focused programGSK is paying Wave Life Sciences $12 million upfront to take ownership of a hepatic program arising from the companies’ long-running collaboration.fiercebiotech · 3d ago
- Roche drops muscle-sparing obesity antibody after flunked interim analysisRoche has slammed the brakes on an obesity antibody after the candidate showed little hope of hitting its endpoints in a phase 2 study.fiercebiotech · 5d ago
- Chutes & Ladders—Travere chief makes way for former Amicus CEOTravere Therapeutics CEO Eric Dube, Ph.D., is stepping down after overseeing the launch of the rare kidney disease drug Filspari.fiercebiotech · 9d ago
- Moonwalk reloads with $70M and new RNAi prospects for obesityThe California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.biopharma_dive · 25d ago
- With $263M, LifeMine unearths a new drug for organ transplantsLed by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs.biopharma_dive · 1mo ago
- ‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series EA little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to focus its dwindling resources on its lead asset. Now, the Massachusetts biotech is shaking…fiercebiotech · 1mo ago
- STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATDBiotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.stat · 2mo ago
- Wave aims for monthly dosing with RNA editing treatment for AATDWave Life Sciences reported an updated cut of data from its early-stage study of an RNA editing treatment for alpha-1 antitrypsin deficiency, suggesting it can dose its genetic therapy monthly. Peo…endpoints · 4mo ago
Data sources
last refreshed 15m ago
Found something off?
comments(0)
5-min edit window · permanent after that